What is "rindopepimut"

Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases.

The vaccine consists of the EGFRv3-specific peptide (a 13- amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH).

The US FDA granted it Breakthrough Therapy Designation for glioblastoma in Feb 2015.